Cargando…

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

Appropriate immune response following COVID-19 vaccination is important in the context of disease-modifying treatments (DMTs). In a prospective cross-sectional study, we determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and...

Descripción completa

Detalles Bibliográficos
Autores principales: Achiron, Anat, Mandel, Mathilda, Dreyer-Alster, Sapir, Harari, Gil, Dolev, Mark, Menascu, Shay, Magalashvili, David, Flechter, Shlomo, Givon, Uri, Guber, Diana, Sonis, Polina, Zilkha-Falb, Rina, Gurevich, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500842/
https://www.ncbi.nlm.nih.gov/pubmed/34655991
http://dx.doi.org/10.1016/j.jneuroim.2021.577746
_version_ 1784580530363170816
author Achiron, Anat
Mandel, Mathilda
Dreyer-Alster, Sapir
Harari, Gil
Dolev, Mark
Menascu, Shay
Magalashvili, David
Flechter, Shlomo
Givon, Uri
Guber, Diana
Sonis, Polina
Zilkha-Falb, Rina
Gurevich, Michael
author_facet Achiron, Anat
Mandel, Mathilda
Dreyer-Alster, Sapir
Harari, Gil
Dolev, Mark
Menascu, Shay
Magalashvili, David
Flechter, Shlomo
Givon, Uri
Guber, Diana
Sonis, Polina
Zilkha-Falb, Rina
Gurevich, Michael
author_sort Achiron, Anat
collection PubMed
description Appropriate immune response following COVID-19 vaccination is important in the context of disease-modifying treatments (DMTs). In a prospective cross-sectional study, we determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and 89 healthy subjects. Protective response was demonstrated in untreated MS patients (N = 76, 100%), treated with Cladribine (N = 48, 100%), Dimethyl fumarate (N = 35, 100%), Natalizumab (N = 32, 100%), and Teriflunomide (N = 39, 100%), similarly to healthy subjects (N = 89, 97.8%). Response was decreased in Fingolimod (N = 42, 9.5%), Ocrelizumab (N = 114, 22.8%) and Alemtuzumab (N = 22, 86.4%) treated patients. IgG response can help tailor adequate vaccine guidelines for MS patients under various DMTs.
format Online
Article
Text
id pubmed-8500842
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-85008422021-10-12 Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study Achiron, Anat Mandel, Mathilda Dreyer-Alster, Sapir Harari, Gil Dolev, Mark Menascu, Shay Magalashvili, David Flechter, Shlomo Givon, Uri Guber, Diana Sonis, Polina Zilkha-Falb, Rina Gurevich, Michael J Neuroimmunol Article Appropriate immune response following COVID-19 vaccination is important in the context of disease-modifying treatments (DMTs). In a prospective cross-sectional study, we determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and 89 healthy subjects. Protective response was demonstrated in untreated MS patients (N = 76, 100%), treated with Cladribine (N = 48, 100%), Dimethyl fumarate (N = 35, 100%), Natalizumab (N = 32, 100%), and Teriflunomide (N = 39, 100%), similarly to healthy subjects (N = 89, 97.8%). Response was decreased in Fingolimod (N = 42, 9.5%), Ocrelizumab (N = 114, 22.8%) and Alemtuzumab (N = 22, 86.4%) treated patients. IgG response can help tailor adequate vaccine guidelines for MS patients under various DMTs. Elsevier B.V. 2021-12-15 2021-10-09 /pmc/articles/PMC8500842/ /pubmed/34655991 http://dx.doi.org/10.1016/j.jneuroim.2021.577746 Text en © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Achiron, Anat
Mandel, Mathilda
Dreyer-Alster, Sapir
Harari, Gil
Dolev, Mark
Menascu, Shay
Magalashvili, David
Flechter, Shlomo
Givon, Uri
Guber, Diana
Sonis, Polina
Zilkha-Falb, Rina
Gurevich, Michael
Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study
title Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study
title_full Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study
title_fullStr Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study
title_full_unstemmed Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study
title_short Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study
title_sort humoral immune response in multiple sclerosis patients following pfizerbnt162b2 covid19 vaccination: up to 6 months cross-sectional study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500842/
https://www.ncbi.nlm.nih.gov/pubmed/34655991
http://dx.doi.org/10.1016/j.jneuroim.2021.577746
work_keys_str_mv AT achironanat humoralimmuneresponseinmultiplesclerosispatientsfollowingpfizerbnt162b2covid19vaccinationupto6monthscrosssectionalstudy
AT mandelmathilda humoralimmuneresponseinmultiplesclerosispatientsfollowingpfizerbnt162b2covid19vaccinationupto6monthscrosssectionalstudy
AT dreyeralstersapir humoralimmuneresponseinmultiplesclerosispatientsfollowingpfizerbnt162b2covid19vaccinationupto6monthscrosssectionalstudy
AT hararigil humoralimmuneresponseinmultiplesclerosispatientsfollowingpfizerbnt162b2covid19vaccinationupto6monthscrosssectionalstudy
AT dolevmark humoralimmuneresponseinmultiplesclerosispatientsfollowingpfizerbnt162b2covid19vaccinationupto6monthscrosssectionalstudy
AT menascushay humoralimmuneresponseinmultiplesclerosispatientsfollowingpfizerbnt162b2covid19vaccinationupto6monthscrosssectionalstudy
AT magalashvilidavid humoralimmuneresponseinmultiplesclerosispatientsfollowingpfizerbnt162b2covid19vaccinationupto6monthscrosssectionalstudy
AT flechtershlomo humoralimmuneresponseinmultiplesclerosispatientsfollowingpfizerbnt162b2covid19vaccinationupto6monthscrosssectionalstudy
AT givonuri humoralimmuneresponseinmultiplesclerosispatientsfollowingpfizerbnt162b2covid19vaccinationupto6monthscrosssectionalstudy
AT guberdiana humoralimmuneresponseinmultiplesclerosispatientsfollowingpfizerbnt162b2covid19vaccinationupto6monthscrosssectionalstudy
AT sonispolina humoralimmuneresponseinmultiplesclerosispatientsfollowingpfizerbnt162b2covid19vaccinationupto6monthscrosssectionalstudy
AT zilkhafalbrina humoralimmuneresponseinmultiplesclerosispatientsfollowingpfizerbnt162b2covid19vaccinationupto6monthscrosssectionalstudy
AT gurevichmichael humoralimmuneresponseinmultiplesclerosispatientsfollowingpfizerbnt162b2covid19vaccinationupto6monthscrosssectionalstudy